title: Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel.
abstract: The optimal strategy to balance bleeding and ischaemic events in patients with atrial fibrillation, requiring antiplatelet therapy on top of anticoagulation, is subject to debate, since specifically designed and powered randomized trials are not available yet. The review aims to highlight the current developments in the light of the 2014 joint consensus document of the European Society of Cardiology (ESC) Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS) and of the 2014 ESC myocardial revascularization guidelines, both published recently.
authors.affiliation: 3rd Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria miklos.rohla@meduniwien.ac.at.
authors.forename: Miklos
authors.initials: M
authors.lastname: Rohla
authors.affiliation: 3rd Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria.
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Weiss
authors.affiliation: Department of Cardiology, Medical University, Vienna, Austria.
authors.forename: Johann
authors.initials: J
authors.lastname: Wojta
authors.affiliation: Department of Cardiology, Medical University, Vienna, Austria.
authors.forename: Alexander
authors.initials: A
authors.lastname: Niessner
authors.affiliation: 3rd Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria.
authors.forename: Kurt
authors.initials: K
authors.lastname: Huber
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications* / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D012307:Risk Factors; D015912:Thrombolytic Therapy / Q000379:methods*; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents
keywords: Antithrombotic therapy; Atrial fibrillation; Coronary stenting